Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug,
ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQX: ATBPF), is pleased to announce that the first eight
subjects have been enrolled and are on treatment in its key Phase 2B clinical trial, a double-blind, gastrointestinal (“GI”) safety
study in 240 subjects with naproxen as a comparator. Naproxen is the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”)
in the USA. The study is designed to demonstrate the unequivocal superiority of ATB-346 in GI safety.
Antibe’s CEO, Dan Legault, commented, “We are excited to report that enrollment has officially commenced for our key Phase 2B GI
safety study for ATB-346, and we remain on our previously announced schedule.”
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent
global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products
servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of
knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries,
operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing
and development of drugs. Any statements contained herein that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect",
"intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that
could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release.
Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not
limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its
inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical
device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update
the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable
law.
Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
dan.legault@antibethera.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170908005168/en/